Taiwan Bio Therapeutics Co., Ltd.

Taiwan Bio Therapeutics Co., Ltd. is a biotechnology company specializing in the research, development, and manufacturing of advanced cell therapy products. Its core focus lies in creating allogeneic stem cell drugs, primarily for treating degenerative diseases such as arthritis and ischemic conditions, including hard-to-heal wounds and acute myocardial infarction. The company integrates its FAST CGT platform, which leverages big data analytics, transgene design, cell engineering, and automated manufacturing to improve therapeutic efficacy, accelerate drug development, and streamline cell therapy production. Taiwan Bio Therapeutics provides contract development and manufacturing organization (CDMO) services, supporting both in-house innovations and external partners throughout the drug discovery and production pipeline. Its business model emphasizes comprehensive support for cell therapy research in early and preclinical stages, facilitating broader patient access to next-generation therapies. Situated in Hsinchu, Taiwan, and founded in 2014, the company plays a pivotal role in advancing regenerative medicine and shaping the cell therapy ecosystem, with growing global collaborations and a commitment to addressing chronic, immune-related, and cardiovascular diseases.